Genentech’s Alecensa (Alectinib) Phase III Results

South San Francisco, CA   June 5, 2017  Genentech Press Release   Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type…

Do You Know Me?

South San Francisco, CA    June 3, 2017  Submitted by Weinerd Pretzel   This person was scoping out our joint at 7am… he checked our door locks… he may have been lost, but may have been up to no good. Off Galway…